Resources on Access to Medicine
The Access to Medicine Index is engaged in dialogue with many stakeholder organizations and initiatives, while grounded firmly in prior research.
Following is a collection of resources related to the development of the Index and to efforts to improve global access to medicines. Index development reports
 | |  | Final benchmarks for the 2008 Access to Medicine Index
Order a hard copy version |  | Facts, adjustments and fine-tuning of benchmark model through industry consultation |  | Preliminary report on performance indicators based on multi-stakeholder process. |
Support for the Index
Access to Medicine
 | |  | SustainAblitiy, ABP, Opers, USS, June 2007 This report is a pension-fund led dialogue between the pharmaceutical industry and its investors that attempts to capture the rich and complex discussion about how the pharmaceutical industry and its investors can take proactive steps to achieve a better alignment between the interests of its shareholders and wider society. It includes recommendation about how to manage productivity challenges, changing societal expectations, developments in technology and the growth in importance of the emerging markets. |  | F&C Research Note, October 2007 The research note covers areas like; what are key area’s of an access to medicines strategy, why is the issue back on the agenda, the industry’s existential crisis, and four recommendations for pharmaceutical companies. |  | Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, Paul Hunt, September 2006
Chapter III b offers draft preliminary guidelines for pharmaceutical companies, on access to medicines. The AtM foundation feels supported by and can contribute to the call for a framework for good practice in the pharmaceutical industry. |  | ICCR, Corporate Examiner, Vol 34, No.6-7, August 2006 This report systematically articulates best practices for the pharmaceutical sector in responding to the HIV-TB-Malaria pandemics, and then evaluates each of fifteen global companies on their level of compliance with these practices. |  | Pharmaceutical R&D Policy Project, LSE, Wellcome Trust, September 2005 Current policy thinking around neglected disease drug development is rooted in a set of shared understandings that have become accepted over the past decade, and which are largely based on the pre-2000 R&D landscape for these diseases. In order to provide policy-makers with the information they need to improve neglected disease drug R&D policies this report sets out to describe the post 2000 landscape of Neglected disease R&D activity.
Summary of The New Landscape of Neglected Disease Drug Development |  | UK Government policy paper, March 2005 The UK Government committed to work in partnership with the business community, including the pharmaceutical industry, to ensure the longer-term supply of affordable essential medicines to developing countries and to build on ‘best practice’ by companies as they engage in developing country markets. This document sets out a framework that seeks to achieve this |  | Pharmafutures, December 2004 This report attempts to capture the rich and complex discussion about the evolution of the pharmaceutical industry over the next ten years, which took place within the Pharma Futures project. |  | Pharmaceutical Shareowners Group, September 2004 In the report, PSG, a group of fourteen global financial institutions, outlines what it believes to be eight key elements of a good corporate strategy for addressing the crisis and responding to the risks and opportunities the issue poses for the sector.
Summary |  | Oxfam, VSO and Save the Children, July 2002 In this report, development agencies Oxfam, Save the Children, and VSO challenge the pharmaceutical industry to improve its efforts to tackle the health crisis affecting children and adults in developing countries. |  | Core Ratings Pharmaceutical sector, May 2003 In this report, CoreRatings analyses how the world’s eleven largest pharmaceutical companies (by market capitalisation) are managing the investment risks arising from the major issues surrounding the acute health problems of developing countries. |  | The Access to Medicine Foundation’s Code of Ethics |  | The Access to Medicine Foundation’s Conflict of Interest Policies |  | The Access to Medicine Foundation’s Governance Charter | |
What the Index measures
The Access to Medicine Index is designed to provide standardized information on individual pharmaceutical companies with regard to their efforts to improve global access to medicines. Learn more |
